Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial von Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.

Volltext

PG 5.01 Targeting CDK 4–6 pathway von Finn, R.S, Slamon, D.J

Volltext

317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients w... von Wainberg, Z.A, Hecht, J.R, Konecny, G.E, Chmielowski, B, Finn, R.S, Martinez, D, Yonemoto, L, Glaspy, J, Slamon, D.J

Volltext

498 CDK4/6 inhibitor (LY2835219) exhibits potent anti-tumor activity in human lung cancer cell lines with intact retinoblastoma von Goldman, J.W, Garon, E.B, Conklin, D, Wong, D.J.L, Wolf, B, Silveira, D.D, Kamranpour, N, Pitts, S, Finn, R.S, Slamon, D.J

Volltext

558 Dual Targeting of ADAM10 and ADAM17 as a Novel Therapy for Breast Cancer von Mullooly, M, O'Brien, N, Finn, R.S, Slamon, D.J, Crown, J, McGowan, P.M, Duffy, M.J

Volltext

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III rando... von Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., Fasching, P.A.

Volltext

Prognostic classification of breast ductal carcinoma-in-situ von Poller, D.N., Barth, A., Slamon, D.J., Silverstein, M.J., Gierson, E.D., Coburn, W.J., Waisman, J.R., Gamagami, P., Lewinsky, B.S.

Volltext

145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer von McDermott, M.S, Browne, B.C, O'Brien, N.A, Slamon, D.J, Henry, M, Meleady, P, Clynes, M, Dowling, P, Crown, J, O'Donovan, N

Volltext

1049 POSTER Increased Amplification of HER2 in a Cell Line Model of Acquired Lapatinib Resistance von McDermott, M, Anderson, L, O'Brien, N, Crown, J, Slamon, D.J, O'Donovan, N

Volltext

FOXA1 represses the molecular phenotype of basal breast cancer cells von Bernardo, G M, Bebek, G, Ginther, C L, Sizemore, S T, Lozada, K L, Miedler, J D, Anderson, L A, Godwin, A K, Abdul-Karim, F W, Slamon, D J, Keri, R A

Volltext

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer von Davidson, T.M., Lebreton, C.L., Hendricksen, A.E. Wahner, Atkinson, H.J., Larson, M.C., Oberg, A.L., Provencher, D.M., Glaspy, J.A., Karlan, B.Y., Slamon, D.J., Konecny, G.E., Ray-Coquard, I.L.

Volltext

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant von Neven, P, Fasching, P.A, Chia, S, Jerusalem, G, De Laurentiis, M, Im, S.-A, Petrakova, K, Bianchi, G.V, Martin, M, Nusch, A, Sonke, G.S, de la Cruz-merino, L, Beck, J.T, Zarate, J.P, Wang, Y, Chakravartty, A, Wang, C, Slamon, D.J

Volltext

Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the... von Slamon, D.J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Ji, Y., Wang, C., Deore, U., Chakravartty, A., Zarate, J.P., Taran, T., Fasching, P.A.

Volltext

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ov... von Konecny, G.E., Hendrickson, A.E. Wahner, Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., Roman, L.D., Rody, A., Karlan, B.Y., Mullany, S.A., Chen, H., Ray-Coquard, I.L., Provencher, D.M., Yachnin, A., Cottu, P.H., Glaspy, J.A., Haluska, P., Slamon, D.J.

Volltext

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy von Burstein, H. J., Lieberman, G., Slamon, D. J., Winer, E. P., Klein, P.

Volltext

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III rando... von Slamon, D.J, Neven, P, Chia, S, Jerusalem, G, De Laurentiis, M, Im, S, Petrakova, K, Bianchi, G. Valeria, Martin, M, Nusch, A, Sonke, G.S, De la Cruz-Merino, L, Beck, J.T, Ji, Y, Wang, C, Deore, U, Chakravartty, A, Zarate, J.P, Taran, T, Fasching, P.A

Volltext

Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast can... von Cristofanilli, M., Slamon, D.J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., André, F., Puyana Theall, K., Huang, X., Giorgetti, C., Huang Bartlett, C., Turner, N.C.

Volltext

Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1 von Ryan, B.M., Konecny, G.E., Kahlert, S., Wang, H.-J., Untch, M., Meng, G., Pegram, M.D., Podratz, K.C., Crown, J., Slamon, D.J., Duffy, M.J.

Volltext

LBA7_PR - Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-ne... von Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G.V., Esteva, F.J., Martin, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., Jerusalem, G.

Volltext

Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HE... von Slamon, D.J., Neven, P., Chia, S., Fasching, P.A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G.V., Esteva, F.J., Martin, M., Nusch, A., Sonke, G.S., De la Cruz-Merino, L., Beck, J.T., Pivot, X., Sondhi, M., Wang, Y., Chakravartty, A., Rodriguez-Lorenc, K., Jerusalem, G.

Volltext